ASP4345 + placebo + risperidone + quetiapine + olanzapine + ziprasidone + aripiprazole + brexpiprazole + paliperidone + lurasidone
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
Jul 13, 2018 → Oct 21, 2019
NCT ID
NCT03557931About ASP4345 + placebo + risperidone + quetiapine + olanzapine + ziprasidone + aripiprazole + brexpiprazole + paliperidone + lurasidone
ASP4345 + placebo + risperidone + quetiapine + olanzapine + ziprasidone + aripiprazole + brexpiprazole + paliperidone + lurasidone is a phase 2 stage product being developed by Astellas Pharma for Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT03557931. Target conditions include Schizophrenia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03557931 | Phase 2 | Completed |
Competing Products
20 competing products in Schizophrenia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| antipsychotic dose increase | Eli Lilly | Pre-clinical | 23 |
| Olanzapine + Placebo | Eli Lilly | Phase 3 | 77 |
| Olanzapine + Aripiprazole | Eli Lilly | Approved | 85 |
| olanzapine therapy | Eli Lilly | Approved | 85 |
| olanzapine-RAIM + placebo | Eli Lilly | Phase 2 | 52 |
| Clozapine + Olanzapine | Eli Lilly | Approved | 85 |
| Atomoxetine | Eli Lilly | Approved | 85 |
| Risperidone + Placebo + LY2140023 | Eli Lilly | Phase 2 | 52 |
| Olanzapine + olanzapine + risperidone | Eli Lilly | Approved | 85 |
| Zotepine + Risperidone | Astellas Pharma | Approved | 85 |
| ASP4345 + Matching Placebo | Astellas Pharma | Phase 1 | 33 |
| ASP6981 + Placebo | Astellas Pharma | Phase 1 | 33 |
| SAPHRIS + Asenapine | Sun Pharmaceutical | Phase 1 | 33 |
| Torrent's Quetiapine Fumarate Tablets | Torrent Pharmaceuticals | Phase 1 | 33 |
| Olanzapine Hydrochloride | Eli Lilly | Phase 1/2 | 41 |
| Rapid-Acting Intramuscular Olanzapine + Placebo | Eli Lilly | Phase 3 | 77 |
| Pomaglumetad methionil | Eli Lilly | Phase 3 | 77 |
| Olanzapine | Eli Lilly | Approved | 85 |
| Intramuscular Olanzapine Depot + Placebo | Eli Lilly | Phase 3 | 77 |
| olanzapine + atomoxetine + placebo | Eli Lilly | Phase 1/2 | 41 |